Skip to main content
. Author manuscript; available in PMC: 2016 Apr 4.
Published in final edited form as: J Immunother. 2010 Nov-Dec;33(9):975–982. doi: 10.1097/CJI.0b013e3181fb0486

Figure 5. Lovasatin does not affect antigen specific cytoxicity of MART1-specific TILs.

Figure 5

TILs from HLA-A2.1+ patients that recognize MART-1 epitope were used in CTL assays. The target cells were either the HLA-A2.1+ melanoma cell line 624 targets endogenously expressing MART-1 (A) or T2 cells pulsed with the MART-1 peptide (B), in the presence of 10 μM lovastatin, 10 μM pravastatin or vehicle control DMSO as indicated. The control were target cells loaded with HLA-A2.1-binding HIV rev peptide. The targets were then incubated with TILs at different E:T ratios for 3 to 4 hours and stained with an anti-cleaved caspase-3 rabbit mAb. The data were from three different TIL lines.